94 Solaris Avenue
Camana Bay KY1-1108
Cayman Islands
345-949-4123
https://www.beigene.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 10 000
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. John V. Oyler | Co-Founder, Executive Chairman & CEO | 2,43M | S.O. | 1968 |
Dr. Xiaobin Wu Ph.D. | President & COO | 1,7M | S.O. | 1962 |
Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 4,42M | S.O. | 1963 |
Ms. Julia Wang | CFO & Principal Financial Officer | 1,07M | S.O. | 1971 |
Mr. Chan Lee | General Counsel & Senior VP | 1,01M | S.O. | 1968 |
Mr. Wang Lai Ph.D. | Global Head of R&D | 1,12M | S.O. | 1977 |
Mr. Titus B. Ball | VP & Chief Accounting Officer | S.O. | S.O. | 1973 |
Ms. Liza Heapes | Head of Investor Relations | S.O. | S.O. | S.O. |
Mr. Yang Ji | Chief Compliance Officer | S.O. | S.O. | S.O. |
Dr. Yan Qi | Senior VP & Head of Public Affairs - Greater China | S.O. | S.O. | S.O. |
BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
L’ISS Governance QualityScore de BeiGene, Ltd. en date du 1 juin 2024 est 7. Les scores principaux sont Audit : 7; Société : 5; Droits des actionnaires : 6; Compensation : 9.